tTG/DGP Fusion Peptide IgA

If you have unexplained digestive trouble, stubborn iron deficiency, or a close relative with celiac disease, this is one of the most direct blood signals that gluten may be quietly damaging your gut. It looks for the specific antibodies your immune system produces only when gluten triggers the autoimmune process behind celiac disease.

A positive result does not automatically mean you have celiac disease, and a normal one does not always rule it out. But knowing this number, and watching how it moves, is often the step that turns years of vague symptoms into a clear answer.

What This Test Actually Measures

This test measures tTG/DGP fusion peptide IgA, meaning a type of immune protein called an antibody (IgA is one of the main antibody classes your body makes) that binds a combined celiac target. That target pairs two things: tissue transglutaminase, an enzyme in your gut tissue (abbreviated tTG), and deamidated gliadin peptides, gluten fragments your gut has chemically altered (abbreviated DGP).

The antibody is made by immune cells, so this reflects an active immune response rather than a measurement of the enzyme or of gluten itself. In celiac disease, dietary gluten from wheat, barley, and rye sets off a reaction in the small intestine, and immune cells begin producing antibodies against both the gluten fragments and your own tissue enzyme.

Pairing the two targets is deliberate. Some people with celiac disease make antibodies against one target but not the other, so combining them can flag cases a single-target test would miss. That said, major guidelines (from the AGA, ACG, and pediatric gastroenterology societies) still recommend transglutaminase IgA alone as the first-line test, since adding gliadin peptide antibodies raises sensitivity only modestly and can reduce specificity and add cost. The combined format is best reserved for situations where the standard test tends to fall short.

Celiac Disease

A strongly elevated level points to celiac disease with high specificity, though weakly positive results are less definitive, especially in people at low risk. Celiac disease is an autoimmune condition affecting roughly 1 in 100 people. These antibodies only appear while you are eating gluten, which is why the test reflects an ongoing, gluten-driven reaction rather than a fixed trait.

The single most established marker in this family is tissue transglutaminase IgA, which across many studies correctly identifies most people with active celiac disease. The added gliadin peptide component mainly earns its place in specific settings, such as very young children, by catching cases the transglutaminase test alone would let slip through.

How the Number Tracks Your Odds of Celiac Disease

This is not a simple positive-or-negative light. The higher the antibody level climbs, the more likely it is that real intestinal damage is present, and when both the transglutaminase and gliadin peptide antibodies are strongly positive together, that probability approaches certainty. The findings below come from tissue transglutaminase and combined transglutaminase/gliadin peptide testing, closely related to this assay.

What this means for you: a strongly positive result, especially with both targets elevated, is a serious signal that warrants prompt follow-up rather than watchful waiting. A borderline or isolated positive is far less certain and needs a fuller workup before any conclusion, which is exactly why the level, not just the yes-or-no, matters.

The Cost of Leaving It Undiagnosed

Untreated celiac disease is not a benign background condition. In a study of about 16,800 adults, those with celiac antibodies in their blood but no diagnosis were roughly 1.6 times as likely to develop cancer overall (hazard ratio 1.57), about 2.3 times as likely to develop gastrointestinal cancer (HR 2.33), and about 1.4 times as likely to develop cardiovascular disease (HR 1.37). This evidence comes from tissue transglutaminase IgA seropositivity, a related measurement.

Serology also carries information during pregnancy. In one cohort, mothers positive for tissue transglutaminase IgA more often carried multiple celiac-related health risks and had offspring with poorer fetal growth and lower infant weight gain. The evidence on undiagnosed seropositivity and pregnancy outcomes is mixed, so these are associations, not proven cause, and reasons to find and treat the disease early rather than to panic over a single number.

What a Standard Transglutaminase Test Can Miss

The tissue transglutaminase IgA test alone is excellent, but not perfect. In one adult study, 18 people with celiac disease were negative on the transglutaminase test, yet 9 of them were caught by gliadin peptide antibodies. The clearest place an added gliadin component helps is in very young children. In people with low IgA, though, it is the IgG-based deamidated gliadin test, not this IgA version, that adds value, since an IgA-based test cannot compensate for a shortage of IgA.

The reverse trap is just as important. A gliadin peptide antibody that is positive on its own, while the transglutaminase test is normal, is a weak signal in most people: in one pediatric study it correctly predicted celiac disease only about 2.5% of the time. A combined result is most convincing when both targets move together, and least reliable when only the gliadin piece is positive.

Why One Reading Is Not Enough

A single antibody level is a snapshot. The trajectory tells you far more. Once gluten is removed, these antibodies fall over months, so a series of results can show whether the underlying reaction is actually calming down. A sensible rhythm is a baseline while still eating gluten, a repeat around 6 to 12 months after any dietary change, and at least yearly tracking after that.

One honest limit: falling or normal serology does not prove your gut has fully healed. In follow-up studies, the transglutaminase test missed about half of people who still had intestinal damage on a gluten-free diet, and 44% with persistent damage in one adult cohort had a normal transglutaminase level. Trend the number to see the direction of travel, but do not treat a normal result as certified healing.

When Results Can Be Misleading

• Already gluten-free: these antibodies only rise while you are eating gluten, so cutting it out before testing can produce a falsely normal result and hide real disease. Stay on a gluten-containing diet until testing is complete.
• Low IgA: if you have a shortage of the antibody class this test uses (called IgA deficiency), an IgA-based result can read falsely low or negative. This is why total IgA is measured alongside, and why IgG-based versions of the test exist as a backup.
• Assay and lab differences: the same sample can give different numbers on different platforms, and cutoffs vary between labs. Compare trends within the same lab and method where possible.
• Isolated gliadin peptide positivity: a positive gliadin peptide antibody with a normal transglutaminase result is often a false alarm in people with normal IgA, and does not by itself establish disease.

What to Do With an Unexpected Result

A positive result is a starting point, not a diagnosis, and it is not a cue to start a gluten-free diet on your own. Doing so before confirmation can erase the very evidence a specialist needs. The right next step is to order or review total IgA and the individual transglutaminase and gliadin peptide antibodies, and to see a gastroenterologist, since a strongly positive pattern usually leads to a small-bowel biopsy or a validated no-biopsy pathway.

If your result is negative but symptoms persist, the workup is not over. Check total IgA first, because a deficiency there can hide disease, and add IgG-based transglutaminase and gliadin peptide testing when it is low. In ambiguous cases, celiac-associated genetic testing (HLA-DQ2 and DQ8) and endomysial antibody testing help sort out who genuinely has the disease from who does not.